Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase NA 1Phase 2/3 1

Status

Recruiting 6Active not recruiting 4Completed 3Unknown 2Not yet recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 108Carcinoma, Non-Small-Cell Lung 95Prostatic Neoplasms 58Multiple Myeloma 45Neoplasms 38Neoplasm Metastasis 33Ovarian Neoplasms 26Melanoma 24Urinary Bladder Neoplasms 23Lung Neoplasms 22Colorectal Neoplasms 22Recurrence 21Leukemia, Lymphocytic, Chronic, B-Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 20Carcinoma, Renal Cell 20Carcinoma, Hepatocellular 17Triple Negative Breast Neoplasms 16Nasopharyngeal Carcinoma 16Lymphoma, Non-Hodgkin 16Stomach Neoplasms 15Leukemia, Myeloid, Acute 15Lymphoma 14Squamous Cell Carcinoma of Head and Neck 13Small Cell Lung Carcinoma 13Fallopian Tube Neoplasms 12Colonic Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11

Interventions

tucatinib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × HER2-positive Breast Cancer × Clear all
NCT06968585 2026-05-08

A166

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
365 enrolled
Breast

HER2-positive Breast Cancer

NCT05705401 2026-04-27

HERO

NRG Oncology

Phase 3 Active not recruiting
1,300 enrolled
Breast

HER2-positive Breast Cancer

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Seagen Inc.

Phase 3 Active not recruiting
466 enrolled 17 charts
Breast

HER2-positive Breast Cancer

NCT06316531 2025-08-19

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
274 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡